Evaluating medication response in ADHD: cognitive, behavioral, and single-subject methodology

Area of Science:

• Neuroscience
• Psychiatry
• Pharmacology

Background:

• Double-blind placebo-controlled trials are standard for evaluating methylphenidate (MPH) in attention-deficit/hyperactivity disorder (ADHD).
• Limited research has explored MPH's impact on cognitive deficits in ADHD using these trial designs.

Observation:

• This article details a technique to assess behavioral and cognitive dose-response relationships for MPH.
• The method allows for single-subject level analysis, providing granular insights into treatment effects.

Findings:

• Case study results and multivariate analyses indicate the utility of this systematic evaluation approach.
• The findings suggest a link between evaluating dose-response relationships and treatment effectiveness.

Implications:

• Systematic assessment of MPH dose-response can lead to more precise medication titration.
• Improved titration may enhance the long-term efficacy of multimodal treatment for ADHD.
• This approach could refine how MPH is prescribed for both behavioral and cognitive symptoms in ADHD.